ORPHA:86875
Adult T-cell leukemia/lymphoma
Also known as: ATLL
Publications
13,454
97.6th percentile
Trials
113
Interventional, condition-specific
Researchers
1,194
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, virus associated tumor due to human T-cell leukemia virus type 1 or human T-cell lymphotropic virus type 1 (HTLV-1) and is characterized by the presence of anti-HTLV-1 antibodies, and malignant, mature, medium-sized T cells with condensed chromatin and polylobated nuclei. The malignant cells exhibit a mature CD4+ T cells and express CD2, CD5, CD25, CD45RO, HLA-DR, and T-cell receptor αβ. Presentation is heterogeneous and is typically of aggressive leukemia or lymphoma, variable skin eruptions, and visceral organ involvement.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019471
- UMLS:C0023493
- NCIT:C3184
Additional Mondo synonyms (5)
T-cell leukaemia of adults · T-cell leukemia of adults · adult T-cell leukaemia · adult T-cell leukemia · adult T-cell leukemia/lymphoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
13,454 matched papers (5,180 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
113 matched on ClinicalTrials.gov (7 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
13,454
13,454 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
13,454 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
5,180 in the last 10 years · medium confidence · 97.6th percentile (publications denominator)
Phrase hits: 13,454 · MeSH hits: 0
Who's working on it?
1,194
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Fuji S18 papers · 2026
Department of Hematology, Osaka International Cancer Institute, Osaka, Japan. Electronic address: fujishige1231@gmail.com.
Papers in Europe PMC - 02Yoshimitsu M16 papers · 2026
Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
Papers in Europe PMC - 03Tokunaga M14 papers · 2026
Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
Papers in Europe PMC - 04Fukuda T13 papers · 2026
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Papers in Europe PMC - 05Fukushima T12 papers · 2026
Laboratory of Hematoimmunology, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Ginowan 901-2720, Japan.
Papers in Europe PMC - 06Itonaga H11 papers · 2026
Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan.
Papers in Europe PMC - 07Uchimaru K11 papers · 2026
Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Papers in Europe PMC - 08Ito A10 papers · 2026
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Papers in Europe PMC - 09Kato T10 papers · 2026
Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Papers in Europe PMC - 10Ishitsuka K9 papers · 2026
Department of Hematology and Rheumatology, Kagoshima University.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
113
interventional trials for this specific condition
113 interventional trials matched this specific condition name; 7 currently recruiting in our sample.
Data as of 27 July 2026
113 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 98.6th percentile).
medium confidence · 98.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
113 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06698003·RECRUITING·A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Conditions: T-Cell Leukemia/Lymphoma, Adult · T-cell Leukemia/Lymphoma · T-cell Leukemia · Lymphoma·Matched via name phrase
- NCT07356245·RECRUITING·Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Conditions: T-cell Lymphoma · Graft Versus Host Disease · Lymphoma, T-Cell · Peripheral T Cell Lymphoma·Matched via name phrase
- NCT05031897·RECRUITING·Two Step Haplo With Radiation Conditioning
Conditions: Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Adult T-Cell Leukemia/Lymphoma · Aplastic Anemia·Matched via name phrase
- NCT07075328·RECRUITING·A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
Conditions: Adult T-Cell Leukemia/Lymphoma (ATLL)·Matched via name phrase
- NCT07159620·RECRUITING·Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
Conditions: Adult T-cell Leukemia/Lymphoma·Matched via name phrase
- NCT04848064·RECRUITING·Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Conditions: Recurrent Adult T-Cell Leukemia/Lymphoma · Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Refractory Adult T-Cell Leukemia/Lymphoma · Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma·Matched via name phrase
- NCT04301076·RECRUITING·Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Conditions: Acute Adult T-Cell Leukemia/Lymphoma · Adult T-Cell Leukemia/Lymphoma · Chronic Adult T-Cell Leukemia/Lymphoma · HTLV-1 Infection·Matched via name phrase
Observational and natural-history studies
6 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05978141·RECRUITING·A Registry for People With T-cell Lymphoma
Conditions: T-cell Lymphoma · NK-Cell Lymphoma · T-cell Prolymphocytic Leukemia · T-cell Large Granular Lymphocytic Leukemia·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Adult T-cell leukemia/lymphoma" OR "T-cell leukaemia of adults" OR "T-cell leukaemia of the adults" OR "T-cell leukemia of adults" OR "T-cell leukemia of the adults" OR "adult T-cell leukaemia" OR "adult T-cell leukemia"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Adult T-cell leukemia/lymphoma" OR "T-cell leukaemia of adults" OR "T-cell leukaemia of the adults" OR "T-cell leukemia of adults" OR "T-cell leukemia of the adults" OR "adult T-cell leukaemia" OR "adult T-cell leukemia"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 113 interventional · 6 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: ATLL
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T03:15:54.724Z
